Serum testosterone and short-term mortality in men with acute myocardial infarction



From this document you will learn the answers to the following questions:

What year is the code for testosterone?

How many smokers were there?

What is the abbreviation for testosterone?

Similar documents
The Relationship Between Low Testosterone and Cardiovascular Disease

Prognostic impact of uric acid in patients with stable coronary artery disease

Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires

Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075

Plasma Testosterone Level in Male Patients with Metabolic Syndrome

25-hydroxyvitamin D: from bone and mineral to general health marker

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011

International Journal of Pharma and Bio Sciences RELATIONSHIP OF TESTOSTERONE LEVELS IN MALES WITH CORONARY HEART DISEASE

Cardiovascular Disease Risk Factors

Guidelines for the management of hypertension in patients with diabetes mellitus

Design and principal results

Diabetes and Heart Disease

INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment

Testosterone and Heart Disease

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007

Education. Panel. Triglycerides & HDL-C

MY TYPE 2 DIABETES NUMBERS

Low Testosterone Concentration and Atherosclerotic Disease Markers in Male Patients With Type 2 Diabetes

Rheumatoid Factor is a Strong Risk Factor for Coronary Artery Disease in Men with Metabolic Syndrome

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis

HDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery

Main Effect of Screening for Coronary Artery Disease Using CT

Men Sexual Dysfunction Associated with Obesity and Metabolic Syndrome

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE

Fewer people with coronary heart disease are being diagnosed as compared to the expected figures.

Improving cardiometabolic health in Major Mental Illness

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME

Protocol: Testosterone and cardiovasclar related events in men: a meta analysis of randomized controlled trials. Version: 1. Date: 5 th December 2011

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study

Clinical Study The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular Disease A Retrospective Single Center Experience

Freiburg Study. The other 24 subjects had healthy markers closer to what would be considered ideal.

Risk Factors for Fire Fighter Cardiovascular Disease

Evaluation of Non-HDL-Cholesterol/HDL-cholesterol ratio as a predictor of coronary artery disease

Statins and Risk for Diabetes Mellitus. Background

Multiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH

The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting

African Americans & Cardiovascular Diseases

Listen to your heart: Good Cardiovascular Health for Life

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Antiretroviral treatment is Associated with increased Arterial Stiffness in Sub- Saharan African HIV-1 Infected Patients: A cross- Sectional Study

An Overview and Guide to Healthy Living with Type 2 Diabetes

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Effect of cigarette smoking on levels of bioavailable testosterone in healthy men

Appendix: Description of the DIETRON model

Body Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ

Original Article INTRODUCTION. Wan Chul Lee 1, Ma Tae Kim 1, Kyung Tae Ko 1, Won Ki Lee 2, Sung Yong Kim 1, Ha Young Kim 1, Dae Yul Yang 1

Vitamin D and Cardiometabolic risk

Pantesin Effective support for heart healthy cholesterol levels*

Neal Rouzier responds to the JAMA article on Men and Testosterone

Understanding diabetes Do the recent trials help?

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Prevalence and Characteristics of Low Serum Testosterone Levels in Men with Type 2 Diabetes Mellitus Naïve to Injectable Therapy

All patients presenting to the Emergency Department with symptoms suggestive of

Androgens and CVD. Brandon Orr- Walker April 2014

YOUR GUIDE TO. Managing and Understanding Your Cholesterol Levels

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

Supplemental Material. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks

Cardiovascular Disease in Men

Postmenopausal Hormone Replacement Therapy and Cardiovascular Disease

A list of FDA-approved testosterone products can be found by searching for testosterone at

Hypogonadism and Testosterone Replacement in Men with HIV

HEALTH UPDATE. Polycystic Ovary Syndrome (PCOS)

Historically, diabetes has been considered

Focus. Andropause: fact or fiction? Introduction. Johan Wilson is an Auckland GP KEY POINTS

Margarines and Heart Disease. Do they protect?

The Prevalence and Determinants of Undiagnosed and Diagnosed Type 2 Diabetes in Middle-Aged Irish Adults

Type 1 Diabetes ( Juvenile Diabetes)

DIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE

February 25, Dear Dr. Hamburg:

Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost

Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Support Supplement

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine

Published Quarterly Mangalore, South India ISSN Volume 4, Issue 1; January-March 2005

Quantifying Life expectancy in people with Type 2 diabetes

METABOLIC SYNDROME IN A CORRECTIONS POPULATION TREATED WITH ANTIPSYCHOTICS

How To Know If You Have Microalbuminuria

WHAT DOES DYSMETABOLIC SYNDROME MEAN?

Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better

Us TOO University Presents: Estrogen Deficiency Side Effects Due to Androgen Deprivation Therapy

Albumin and All-Cause Mortality Risk in Insurance Applicants

How To Determine The Prevalence Of Microalbuminuria

Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Learn and Live SM. ACCF/AHA Pocket Guideline

Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research?

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

Multimarker Approach to Risk Stratification Among Patients with Advanced Chronic Heart Failure

What is a Heart Attack? 1,2,3

Coronary heart disease (CHD) has an enormous

Transcription:

ORIGINAL ARTICLE Cardiology Journal 2010, Vol. 17, No. 3, pp. 249 253 Copyright 2010 Via Medica ISSN 1897 5593 Serum testosterone and short-term mortality in men with acute myocardial infarction Constantin Militaru 1, Ionut Donoiu 2, Ovidiu Dracea 1, Dan-Dominic Ionescu 2 1 Craiova Cardiology Center, Romania 2 Department of Cardiology, Craiova University of Medicine and Pharmacy, Craiova Cardiology Center, Romania Abstract Background: A significant and independent association between testosterone levels and coronary events in men and women has not been confirmed in large prospective studies, although some reports have shown that endogenous testosterone concentrations in men are inversely related to cardiovascular and general mortality. Methods: We aimed to assess the relationship between serum testosterone level and short- -time (30-day) mortality in men with acute myocardial infarction. Results: We included 126 consecutive male patients admitted with acute myocardial infarction. The mean age was 62 ± 13 years. We determined, at admission, serum free testosterone (T) level (using a chemoluminiscence assay), high sensitivity C-reactive protein, N-terminal pro- -B-type natriuretic peptide, and glycated hemoglobin level. We analyzed the 30-day mortality. Conclusions: The mean level of serum T was 4.1 ± 2.9 ng/ml. All non-survivors had T level 3 ng/ml. A low level of T was independently related to total short-term mortality. (Cardiol J 2010; 17, 3: 249 253) Key words: testosterone, myocardial infarction, mortality Editorial p. 217 Introduction A significant and independent association between endogenous testosterone (T) levels and coronary events in men and women has not been confirmed in large prospective studies. There is some data suggesting that coronary artery disease is associated with low T level in men. Hypoandrogenemia was shown to be associated with visceral obesity, insulin resistance, low high-density lipoprotein (HDL) cholesterol and elevated triglycerides, low-density lipoprotein (LDL) cholesterol, and plasminogen activator type 1. The effects of exogenous T on cardiovascular mortality or morbidity have not been extensively investigated in prospective controlled studies. Some data suggests there may be beneficial effects in men with coronary artery disease. In animal experiments, exogenous testosterone had neutral or beneficial effects on the atherosclerosis process. Exogenous androgens decrease serum levels of HDL-cholesterol, plasminogen activator type 1, lipoprotein (a), fibrinogen, insulin, leptin, and visceral fat mass. Exogenous testosterone, in high concentrations, produces vasodilation; at physiological concentrations, there are mixed effects on vascular reactivity. Address for correspondence: Dr. Ionut Donoiu, MD, Teaching assistant, Department of Cardiology, University of Medicine and Pharmacy of Craiova, Craiova Cardiology Center, Tabaci 1, 200640 Craiova, Romania, tel: +4074 6126 669, e-mail: i.donoiu@gmail.com Received: 24.07.2009 Accepted: 12.10.2009 249

Cardiology Journal 2010, Vol. 17, No. 3 Methods Patients We included 126 consecutive male patients admitted to the Craiova Cardiology Center between January and December 2008 with a diagnosis of acute myocardial infarction (MI), established based on current guidelines of the European Society of Cardiology. Patients were excluded if they had been castrated as treatment for testicular or prostate cancer or if they were taking any medications known to affect sex hormone concentrations (e.g. antiandrogenic agents for prostate cancer). Approval for the study was obtained from the local Research Ethics Committee, and informed consent was obtained from all participants. All patients/patient s family were contacted by phone 30 days after admission. The mortality data was based on the charts of the hospital or on information provided by the patient s family. Evaluation We determined, at admission, serum free testosterone level, high sensitivity C-reactive protein (hscrp), N-terminal pro-b-type natriuretic peptide (NT-proBNP), glycemia and glycated hemoglobin level, total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides. The blood sample was obtained at approximately the same hour in the morning. Testosterone level was measured using a chemoluminiscence assay. Serum level of NT- -probnp was determined at admission using a commercially available assay device with a measuring range between 60 3,000 pg/ml. A standard transthoracic echocardiography exam was performed in the 48 hours following admission; left ventricular ejection fraction (LVEF) was measured using the modified Simpson method. Statistical analysis Statistical analyses were performed using SPSS 15.0 for Windows. Student s t test was used to analyze differences between mean values, and ANOVA was used to analyze differences between multiple groups. Pearson s correlation coefficient was calculated to determine associations between continuous variables. A probability value of 0.05 or less was considered significant. Results The mean age of the patients included was 62 ± ± 13 years. Table 1. Patient characterisics. Age (years) 61.7 ± 12.9 ST segment elevation MI (%) 41.2 Arterial hypertension (%) 68.2 Diabetes mellitus (%) 33.3 Smokers (%) 65.8 Body mass index [kg/m 2 ] 26.7 ± 7.8 Baseline glycemia [mg/dl] 114.7 ± 41.7 Total cholesterol [mg/dl] 190.4 ± 50.5 Triglycerides [mg/dl] 183.0 ± 79.1 HDL [mg/dl] 41.8 ± 14.8 LDL [mg/dl] 118.3 ± 38.0 hscrp [mg/l] 31.8 ± 25.4 Glycated hemoglobin (%) 6.3 ± 0.8 NT-proBNP [pg/ml] 1827.0 ± 983.1 Tesosterone [ng/ml] 4.1 ± 2.9 LVEF (%) 35.4 ± 10.6 MI myocardial infarction; HDL high-density lipoprotein cholesterol; LDL low-density lipoprotein cholesterol; hscrp high sensitivity C-reactive protein; NT-proBNP N-terminal pro-b-type natriuretic peptide; LVEF left ventricular ejection fraction Due to the relatively small number of patients, we decided to divide the group in relation to the type of myocardial infarction, into an ST segment elevation MI group and a non-st segment elevation MI group. The characteristics of the patients and the values (mean ± standard deviation) of the laboratory measurements are presented in Table 1. The total 30 day mortality was 12.69% (16 patients). Based on the available medical data (hospital charts, death certificates), and on other information related to the mode of death, 12 patients died of cardiovascular causes and four of non-cardiovascular causes (including those with not witnessed sudden death). The characteristics of survivors and non-survivors (mean ± standard deviation) and the statistical significance of the differences between the two groups are presented in Table 2. The non-survivors were predominantly in the group of non-st segment elevation MI (68.8% vs 51.3%, p < 0.01), and had a higher proportion of previously diagnosed diabetes mellitus (32.7% vs 37.5%, p = 0.043). They had significantly lower HDL-cholesterol levels; hscrp and NT-proBNP, which are known risk markers for cardiovascular mortality, were higher in non-survivors. All non-survivors in our population had T level 3 ng/ml, and the mean value was significantly lower than in patients who survived (2.1 ± 0.8 vs 4.3 ± 3.3, p < 0.01). 250

Constantin Militaru et al., Testosterone in acute myocardial infarction Table 2. Characteristics of survivors and non-survivors. Survivors Non-survivors p Age (years) 60.1 ± 12.1 64.4 ± 9.2 NS ST segment elevation MI (%) 42.7 31.2 < 0.01 Arterial hypertension (%) 68.1 68.7 NS Diabetes mellitus (%) 32.7 37.5 0.043 Smokers (%) 66.3 62.5 NS Body mass index [kg/m 2 ] 26.4 ± 5.6 27.3 ± 4.3 NS Baseline glycemia [mg/dl] 113.9 ± 53.1 116.4 ± 32.7 NS Total cholesterol [mg/dl] 193.5 ± 44.7 188.3 ± 60.2 NS Triglycerides [mg/dl] 180.5 ± 68.8 184.2 ± 85.4 NS HDL [mg/dl] 43.2 ± 12.4 40.8 ± 6.8 0.037 LDL [mg/dl] 121.1 ± 41.3 116.3 ± 32.0 NS hscrp [mg/l] 28.5 ± 43.8 54.2 ± 74.4 < 0.01 Glycated hemoglobin (%) 6.2 ± 1.3 6.4 ± 0.4 NS NT-proBNP [pg/ml] 524.0 ± 233.1 2314.1 ± 1381.7 < 0.01 Testosterone [ng/ml] 4.3 ± 3.3 2.1 ± 0.8 0.031 LVEF (%) 37.4 ± 9.8 32.6 ± 11.5 < 0.01 MI myocardial infarction; HDL high-density lipoprotein cholesterol; LDL low-density lipoprotein cholesterol; hscrp high sensitivity C-reactive protein; NT-proBNP N-terminal pro-b-type natriuretic peptide; LVEF left ventricular ejection fraction; NS not significant Table 3. Distribution of variables by quartile group of serum testosterone level. Quartile groups of testosterone 1 2 3 4 p for trend Age (years) 62.7 ± 10.9 61.7 ± 9.6 61.4 ± 11.6 60.3 ± 10.8 0.06 ST segment elevation MI (%) 42.2 40.4 41.6 39.4 0.08 Arterial hypertension (%) 69.4 68.2 69.3 70.1 0.2 Diabetes mellitus (%) 34.5 32.5 32.1 30.5 0.004 Smokers (%) 65.2 65.5 67.1 60.2 0.09 Body mass index [kg/m 2 ] 29.1 ± 6.7 27.7 ± 4.3 27.1 ± 3.2 25.4 ± 4.8 0.002 Baseline glycemia [mg/dl] 116.2 ± 32.7 113.7 ± 24.6 114.7 ± 45.8 115.1 ± 21.1 0.3 Total cholesterol [mg/dl] 193.8 ± 42.2 190.2 ± 30.2 187.4 ± 25.4 187.3 ± 32.6 0.003 Triglycerides [mg/dl] 186.3 ± 65.1 183.8 ± 43.6 180.8 ± 35.2 178.4 ± 29.1 0.004 HDL [mg/dl] 38.3 ± 12.2 38.9 ± 10.3 36.6 ± 14.6 35.2 ± 9.8 < 0.001 LDL [mg/dl] 115.6 ± 27.4 117.4 ± 30.2 117.9 ± 23.5 119.6 ± 34.1 < 0.001 hscrp [mg/l] 33.2 ± 17.4 31.1 ± 23.1 29.5 ± 15.3 27.3 ± 8.9 < 0.001 Glycated hemoglobin (%) 6.3 ± 2.1 6.1 ± 0.9 6.2 ± 0.4 5.9 ± 0.9 0.4 NT-proBNP [pg/ml] 1814.0 ± 745.1 1809.2 ± 423.5 1832.2 ± 632.2 1756.5 ± 562.9 0.03 LVEF (%) 33.2 ± 9.3 34.7 ± 11.2 35.7 ± 6.8 35.9 ± 7.8 0.06 MI myocardial infarction; HDL high-density lipoprotein cholesterol; LDL low-density lipoprotein cholesterol; hscrp high sensitivity C-reactive protein; NT-proBNP N-terminal pro-b-type natriuretic peptide; LVEF left ventricular ejection fraction Table 3 shows the distribution of variables by quartile group of serum testosterone level. Testosterone concentrations were significantly inversely related to body mass index, triglycerides, prevalence of diabetes mellitus, and hscrp, and were positively related to total cholesterol, LDL cholesterol, and HDL cholesterol concentrations. Table 4 shows the odds ratio for all-cause mortality adjusted for age and the other covariates. Age- -adjusted odds ratio for mortality due to all causes decreased significantly with increasing quartile 251

Cardiology Journal 2010, Vol. 17, No. 3 Table 4. Odds ratio (OR) of mortality due to all causes by quartile group of serum testosterone. Quartile groups of testosterone 1 2 3 4 p for trend Age-adjusted OR 1 0.82 (0.67 1.03) 0.67 (0.52 0.86) 0.70 (0.56 0.89) < 0.01 Age and covariate-adjusted OR 1 0.72 (0.51 1.00) 0.61 (0.43 0.81) 0.56 (0.40 0.83) < 0.01 ORs were estimated with logistic regression. The p values for trend are based on c 2 test. Covariates are age, body mass index, LDL and HDL cholesterol, tryglicerides, cigarette smoking, diabetes mellitus, history of hypertension, left ventricular ejection fraction, high sensitivity C-reactive protein and N-terminal pro-b-type natriuretic peptide levels. group of testosterone, and strengthened slightly after multivariable adjustment for covariates. For total mortality, the odds ratio (95% confidence intervals) for increasing quartiles of endogenous total testosterone compared with the lowest quartile were 0.72 (0.51 to 1.00), 0.61 (0.43 to 0.81), and 0.56 (0.40 to 0.83), respectively, after adjustment for age, body mass index, total cholesterol, LDL and HDL cholesterol, tryglicerides, cigarette smoking, diabetes mellitus, history of hypertension, LVEF, hscrp and NT-proBNP levels. Discussion Our study shows that men with acute MI and a low endogenous testosterone level have a higher risk of short-term (30-day) mortality. Serum testosterone was significantly related to mortality, independent of age, body mass index, lipid profile, cigarette smoking, diabetes mellitus, history of hypertension, LVEF, hscrp and NT-proBNP levels. Considering that, in our study, all non-survivors had T level 3 ng/ml, this cut-off value could be used as a marker of mortality risk in acute myocardial infarction. That remains to be validated with the further collection of data. The level of testosterone was inversely related to that of hscrp. We consider this to be an important finding that needs to be explored in future studies. We also found a weak but significant positive correlation between T level and total serum cholesterol. Several studies linked hypoandrogenemia with visceral obesity, insulin resistance, impaired lipid profile, and coagulation [1 4]. High T levels were found to be associated with high HDL-cholesterol levels, low LDL-cholesterol, and low triglyceride levels [5 7]. More cross-sectional studies have reported an association between hypotestosteronemia and cardiovascular morbidity [8, 9]. Several studies report that male survivors of MI have lower T levels than controls, while others report an increased oestradiol to testosterone ratio which was mainly due to lower T levels rather than to increased oestrogen levels. Sewdarsen et al. [8] found significantly lower plasma levels of testosterone in men suffering an acute myocardial infarction. Other studies suggest that although low T levels are associated with an increase in biochemical risk factors of cardiovascular disease, they are not associated with an increased risk of cardiovascular mortality or morbidity. Several cross-sectional and prospective studies have found no significant relationships between endogenous testosterone concentrations and cardiovascular disease events [10, 11]. In an analysis on the population of the European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) study [12] that included 11,606 men, the authors found that endogenous testosterone concentrations are inversely related to mortality due to cardiovascular disease, and that of all causes, and that a low testosterone level may be a predictive marker for cardiovascular disease. The risk of total mortality was 25% to 30% lower in the highest compared with the lowest quartile of testosterone level, and a 1-SD increase in testosterone level was associated with a 14% lower risk of total mortality. Testosterone concentrations were significantly associated with several cardiovascular risk factors (total, LDL and HDL cholesterol, triglycerides, body mass index, and diabetes prevalence). The effects of exogenous T on cardiovascular mortality or morbidity have not been extensively investigated in prospective controlled studies [13]. Conclusions Low endogenous testosterone level is independently associated with a higher short-term mortality in men with acute myocardial infarction. A serum level of testosterone lower than 3 ng/ml could be used as a marker of mortality risk in acute myocardial infarction. 252

Constantin Militaru et al., Testosterone in acute myocardial infarction Acknowledgements The authors do not report any conflict of interest regarding this work. We would like to thank Professor Ion Romulus Scorei, from the Biochemistry Department of the University of Craiova, for his support in our research activities. References 1. Hautanen A, Manttari V, Manninin V et al. Adrenal androgens and testosterone as coronary risk factors in the Helsinki heart study. Atherosclerosis, 1994; 105: 191 200. 2. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb, 1994; 14: 701 706. 3. Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: A review. Atherosclerosis, 1996; 125: 1 13. 4. Hauner H, Stangl K, Burger K, Busch U, Blomer H, Pfeiffer EF. Sex hormone concentrations in men with angiographically assessed coronary artery disease: Relationship to obesity and body fat distribution. Klin Wochenschr, 1991; 69: 664 668. 5. Van Pottelbergh I, Braeckman D, De Bacquer D, De Backer G, Kaufman JM. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis, 2003; 166: 95 102. 6. Tchernof A, Labrie F, Belanger A et al. Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis, 1997; 133: 235 244. 7. Haffner SM, Mykkanen L, Valdez RA, Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab, 1993; 77: 1610 1615. 8. Sewdarsen M, Vythilingum S, Jialal I, Desai RK. Abnormalities in sex hormones are a risk factor for premature manifestation of coronary artery disease in South African Indian men. Atherosclerosis, 1990; 83: 111 117. 9. Aksut SV, Aksut G, Karamehmetoglu A, Oram E. The determination of serum estradiol, testosterone and progesterone in acute myocardial infarction. Jpn Heart J, 1986; 27: 825 837. 10. Mikulec KH, Holloway L, Krasnow RE et al. Relationship of endogenous sex hormones to coronary heart disease: A twin study. J Clin Endocrinol Metab, 2004; 89: 1240 1245. 11. Arnlov J, Pencina MJ, Amin S et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med, 2006; 145: 176 184. 12. Khaw KT, Dowsett M, Folkerd E et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation, 2007; 116: 2694 2701. 13. Haddad RM, Kennedy CC, Caples SM et al. Testosterone and cardiovascular risk in men: A systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc, 2007; 82: 29 39. 253